TFS Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

TFS Capital’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-23,324	Closed	-$253K	–	962
2016 Q3	$253K	Buy	+23,324	New	+$190K	0.06%	467
2016 Q2	–	Sell	-14,229	Closed	-$66K	–	1273
2016 Q1	$66K	Sell	14,229 -51,728	-78%	-$253K	0.01%	934
2015 Q4	$416K	Buy	65,957 +28,585	+76%	+$232K	0.04%	456
2015 Q3	$330K	Sell	37,372 -92,602	-71%	-$972K	0.03%	640
2015 Q2	$1.53M	Sell	129,974 -129,942	-50%	-$1.8M	0.15%	225
2015 Q1	$3.76M	Buy	259,916 +204,409	+368%	+$3.13M	0.37%	52
2014 Q4	$947K	Sell	55,507 -64,605	-54%	-$932K	0.09%	368
2014 Q3	$1.5M	Buy	120,112 +88,685	+282%	+$1.09M	0.13%	241
2014 Q2	$461K	Buy	+31,427	New	+$482K	0.04%	680
2013 Q4	–	Sell	-6,047	Closed	-$274K	–	1710
2013 Q3	$274K	Buy	+6,047	New	+$197K	0.01%	1137

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TFS Capital's STML Position: Q4 2016 in Review

TFS Capital sold out of Stemline Therapeutics, Inc. (STML) in Q4 2016, closing a stake of 23,324 shares — an estimated $253K sold.

TFS Capital first reported a position in STML in Q3 2013 and held it in 10 quarters. The position peaked at $3.76M in Q1 2015. 74 funds tracked by Wall St. Rank hold STML as of Q4 2016.

TFS Capital reported no remaining Stemline Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
TFS Capital sold 23,324 Stemline Therapeutics, Inc. shares in Q4 2016, an estimated $253K.
TFS Capital first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 10 quarters.
TFS Capital's Stemline Therapeutics, Inc. position peaked at $3.76M in Q1 2015.
74 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.